



mAbsolve's Novel Fc Silencing Platform, STR, Will Be Available for Engineering of Antibodies from OmniAb's Antibody Discovery Platform

February 23, 2023

[mAbsolve Ltd](#), developers of a novel Fc silencing variant, today announced a licensing agreement with OmniAb, Inc. for STR, mAbsolve's Fc-silencing platform technology. The agreement provides OmniAb with exclusive, sublicensable access to the STR technology for antibodies that have been generated using OmniAb's cutting-edge antibody discovery platform.

Fc-mediated immune effector activities are an important part of an antibody's natural function, but in many therapeutic antibodies these interactions are not desirable and can lead to adverse side effects. Many approaches to eliminate effector function have been developed, and all of them have limitations. The STR Fc silencing platform, developed by mAbsolve and described in a [recent PLOS One article](#), delivers one of the most truly silent Fc mutations described to date. The technology therefore has the potential to improve the safety and efficacy of therapeutic antibodies and Fc fusion proteins.

Under the terms of this license agreement, OmniAb will exclusively be able to provide access to the STR Fc silencing technology to its partners for antibodies generated from the OmniAb antibody platform. It is intended that, by eliminating effector function, the mAbsolve technology would assist some of OmniAb's partners in downstream engineering of their clinical candidates.

"At OmniAb, we are committed to continuing to expand our offerings through internal investment and creative and intelligent technology expansion approaches that are informed by deep relationships with our partners. Fc silencing is a desirable attribute for some therapeutic approaches. The STR platform can provide our current and future partners with the ability to silence effector functions and enable the development of potentially life-saving medicines." said Todd Pettingill, Vice President of Business Development and Strategy at OmniAb, Inc. "We're pleased to add the STR platform to our tech stack of available novel antibody technologies."

"mAbsolve is committed to improving the safety and effectiveness of therapeutic antibodies, and we strongly believe that the STR technology can be of real benefit to a large proportion of antibody and Fc fusion proteins in development," said Dr. Geoff Hale, Chief Executive Officer at mAbsolve. "Our STR mutations provide a truly silent Fc region and so we look forward to working with OmniAb, Inc. to help their partners discover and develop safe and effective biologics."

About OmniAb, Inc.

OmniAb's discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of OmniAb's proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic® (transgenic rat) and OmniClic® (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur™ features unique structural attributes of cow antibodies for complex targets. OmniAb believes the OmniAb animals comprise the most diverse host systems available in the industry and that



they can be optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates OmniAb's technology and creates opportunities in emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others. The OmniAb suite of technologies span from BI-powered repertoire generation to cutting edge antibody discovery and optimization, offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.

For more information, please visit www.omniab.com.

About mAbsolve Ltd.

mAbsolve was founded in the UK by pioneers of therapeutic antibody development and engineering from both Oxford and Cambridge. We have experienced the clinical challenges caused by incomplete silencing of antibodies using LALA, aglycosylated or IgG4 variants. To address this we have developed a best-in-class solution for silencing of antibody effector function. Visit www.mabsolve.com for more information.

Contact:

Ian Wilkinson
Chief Scientific Officer
wilkinson@mabsolve.com

###